Clinical Trials Browser

Phase 1 × Completed × trifluridine tipiracil drug combination × Clear all

Advanced or Metastatic Solid Tumors

NCT01867866 2024-09-05

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Phase 1 Completed

44 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Phase 1 Completed

44 enrolled

BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Phase 1 Completed

46 enrolled

BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01916447 2024-09-05

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Phase 1 Completed

65 enrolled

Gastrointestinal

Advanced Gastrointestinal Tumors

NCT02031055 2024-09-05

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Phase 1 Completed

8 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02301104 2024-09-05

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Phase 1 Completed

24 enrolled

Gastrointestinal

Liver Diseases, Liver Neoplasms

NCT02301117 2024-09-05

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Phase 1 Completed

43 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Diseases, Renal Insufficiency

NCT05130060 2024-08-14

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

Phase 1 Completed

15 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03317119 2024-04-08

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Phase 1 Completed

26 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Phase 1 Completed

20 enrolled 9 charts

Gastrointestinal

Gastric Adenocarcinoma

NCT03810742 2023-11-18

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Phase 1 Completed

44 enrolled

Other solid neoplasm

Refractory Solid Tumors

NCT03297710 2023-01-05

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

Phase 1 Completed

7 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03616574 2022-09-21

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02602327 2022-08-01

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Phase 1 Completed

21 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT03974594 2022-04-19

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Phase 1 Completed

64 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03305913 2021-03-26

REMETY

Phase 1 Completed

12 enrolled

Gastrointestinal

Pretreated Metastatic Colorectal Cancer

NCT03031691 2020-08-11

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Phase 1 Completed

7 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

A Phase I Study of TAS-102 in Solid Tumors

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

REMETY

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer